Pharma — April 2024
-
Sandoz : Pyzchiva Approved In Europe For Gastroenterology, Dermatology, And Rheumatology Treatments https://www.proinvestor.com/investornyt/1148295/sandoz-pyzchiva-approved-in-europe-for-gastroenterology-dermatology-and-rheumatology-treatments
-
What's Next For Johnson & Johnson Stock After Beating Q1 Earnings? https://www.proinvestor.com/investornyt/1148302/whats-next-for-johnson-amp-johnson-stock-after-beating-q1-earnings
-
Vertex Pharma Obtains Exclusive License To TreeFrog's Cell Manufacturing Technology, C-Stem https://www.proinvestor.com/investornyt/1148845/vertex-pharma-obtains-exclusive-license-to-treefrogs-cell-manufacturing-technology-c-stem
-
Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia https://www.proinvestor.com/investornyt/1148849/sanofi-rilzabrutinib-luna-3-phase-3-study-meets-primary-endpoint-in-immune-thrombocytopenia
-
Novartis Q1 Profit Rises, Tops Estimates; Lifts FY24 View; Proposes Giovanni Caforio As New Chair https://www.proinvestor.com/investornyt/1148848/novartis-q1-profit-rises-tops-estimates-lifts-fy24-view-proposes-giovanni-caforio-as-new-chair
-
FDA Approves Novartis' Lutathera For Pediatric Gastroenteropancreatic Neuroendocrine Tumors https://www.proinvestor.com/investornyt/1149390/fda-approves-novartis-lutathera-for-pediatric-gastroenteropancreatic-neuroendocrine-tumors
-
ALK spås fortsat bedring i det europæiske tabletsalg af Jefferies https://www.proinvestor.com/investornyt/1149400/alk-spas-fortsat-bedring-i-det-europaeiske-tabletsalg-af-jefferies
-
Hanmi, Merck Collaborate To Evaluate BH3120 + Keytruda Combination In Metastatic Solid Tumors https://www.proinvestor.com/investornyt/1149381/hanmi-merck-collaborate-to-evaluate-bh3120-keytruda-combination-in-metastatic-solid-tumors
-
Will Higher Keytruda Sales Drive Merck's Q1 https://www.proinvestor.com/investornyt/1150001/will-higher-keytruda-sales-drive-mercks-q1
-
Astrazeneca stiger efter høj efterspørgsel på kræftmidler i første kvartal https://www.proinvestor.com/investornyt/1150060/astrazeneca-stiger-efter-hoj-eftersporgsel-pa-kraeftmidler-i-forste-kvartal
-
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript https://www.proinvestor.com/investornyt/1150661/gilead-sciences-gild-q1-2024-earnings-call-transcript
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind